Low risk of primary clostridium difficile infection with tetracyclines: A systematic review and metaanalysis

Clinical Infectious Diseases

Volumn 66, Issue 4, 2018, Pages 514-522

  Tariq, Raseen ^a,b   Cho, Janice ^a   Kapoor, Saloni ^a   Orenstein, Robert ^c   Singh, Siddharth ^d   Pardi, Darrell S ^a   Khanna, Sahil ^a  

^a MAYO CLINIC   (United States)

^b ROCHESTER GENERAL HOSPITAL   (United States)

^c MAYO CLINIC HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clostridium difficile infection; Incidence; Metaanalysis; Tetracyclines

Indexed keywords

ANTIBIOTIC AGENT; DOXYCYCLINE; TETRACYCLINE DERIVATIVE; ANTIINFECTIVE AGENT;

ARTICLE; CASE CONTROL STUDY; CLOSTRIDIUM DIFFICILE INFECTION; EMBASE; HUMAN; MEDLINE; META ANALYSIS; NEWCASTLE-OTTAWA SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SYSTEMATIC REVIEW; WEB OF SCIENCE; CLOSTRIDIOIDES DIFFICILE; CLOSTRIDIUM INFECTION; INCIDENCE; OBSERVATIONAL STUDY; ODDS RATIO; PSEUDOMEMBRANOUS COLITIS; RISK FACTOR;

ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; INCIDENCE; OBSERVATIONAL STUDIES AS TOPIC; ODDS RATIO; RISK FACTORS; TETRACYCLINES;

EID: 85046115187     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix833     Document Type: Article

References (39)

1. Lessa FC, Winston LG, McDonald LC; Emerging Infections Program C. difficile Surveillance Team. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372:2369–70.
2. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012; 55 Suppl 2:S88–92.
3. Khanna S, Pardi DS. Clostridium difficile infection: new insights into management. Mayo Clin Proc 2012; 87:1106–17.
4. Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. Association of gastric acid suppression with recurrent Clostridium difficile infection: a systematic review and meta-analysis. JAMA Intern Med 2017; 177:784–91.
5. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365:1693–703.
6. Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41:1254–60.
7. Deshpande A, Pasupuleti V, Thota P, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 2013; 68:1951–61.
8. Joshi N, Miller DQ. Doxycycline revisited. Arch Intern Med 1997; 157:1421–8.
9. Dunston CR, Griffiths HR, Lambert PA, Staddon S, Vernallis AB. Proteomic analysis of the anti-inflammatory action of minocycline. Proteomics 2011; 11:42–51.
10. Chow AW, Benninger MS, Brook I, et al; Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis 2012; 54:e72–e112.
11. Doernberg SB, Winston LG, Deck DH, Chambers HF. Does doxycycline protect against development of Clostridium difficile infection? Clin Infect Dis 2012; 55:615–20.
12. Delaney JA, Dial S, Barkun A, Suissa S. Antimicrobial drugs and community-acquired Clostridium difficile-associated disease, UK. Emerg Infect Dis 2007; 13:761–3.
13. Stroup DF, Berlin JA, Morton SC, et al; Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000; 283:2008–12.
14. Baxter R, Ray GT, Fireman BH. Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol 2008; 29:44–50.
15. Kuntz JL, Chrischilles EA, Pendergast JF, Herwaldt LA, Polgreen PM. Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study. BMC Infect Dis 2011; 11:194.
16. Dial S, Kezouh A, Dascal A, Barkun A, Suissa S. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 2008; 179:767–72.
17. Tartof SY, Rieg GK, Wei R, Tseng HF, Jacobsen SJ, Yu KC. A Comprehensive assessment across the healthcare continuum: risk of hospital-associated Clostridium difficile infection due to outpatient and inpatient antibiotic exposure. Infect Control Hosp Epidemiol 2015; 36:1409–16.
18. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. [Internet] Ottawa Hospital Research Institute, 2014. [cited 2017 Apr 25] Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177–88.
20. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991; 337:867–72.
21. Sun X, Ioannidis JP, Agoritsas T, Alba AC, Guyatt G. How to use a subgroup analysis: users’ guide to the medical literature. JAMA 2014; 311:405–11.
22. Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46 Suppl 1:S19–31.
23. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998; 40:1–15.
24. Noren T, Alriksson I, Akerlund T, Burman LG, Unemo M. In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993–2007 in Sweden. Clin Microbiol Infect 2010; 16:1104–10.
25. Barbut F, Mastrantonio P, Delmée M, Brazier J, Kuijper E, Poxton I; European Study Group on Clostridium difficile. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 2007; 13:1048–57.
26. Hojer H, Wetterfors J. Concentration of doxycycline in bowel tissue and postoperative infections. Scand J Infect Dis Suppl 1976; 9:100–5.
27. Lin H, Jin D, Freitag TE, et al. A compositional shift in the soil microbiome induced by tetracycline, sulfamonomethoxine and ciprofloxacin entering a plant-soil system. Environ Pollut 2016; 212:440–8.
28. Jump RL, Kraft D, Hurless K, Polinkovsky A, Donskey CJ. Impact of tigecycline versus other antibiotics on the fecal metabolome and on colonization resistance to Clostridium difficile in mice. Pathog Immun 2017; 2:1–20.
29. Herpers BL, Vlaminckx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009; 48:1732–5.
30. Nord CE, Sillerström E, Wahlund E. Effect of tigecycline on normal oropharyn-geal and intestinal microflora. Antimicrob Agents Chemother 2006; 50:3375–80.
31. Bassis CM, Theriot CM, Young VB. Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection. Antimicrob Agents Chemother 2014; 58:2767–74.
32. Zhanel GG, Cheung D, Adam H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs 2016; 76:567–88.
33. Ramanathan S, Johnson S, Burns SP, et al. Recurrence of Clostridium difficile infection among veterans with spinal cord injury and disorder. Am J Infect Control 2014; 42:168–73.
34. Sloan B, Scheinfeld N. The use and safety of doxycycline hyclate and other second-generation tetracyclines. Expert Opin Drug Saf 2008; 7:571–7.
35. Welling PG, Koch PA, Lau CC, Craig WA. Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects. Antimicrob Agents Chemother 1977; 11:462–9.
36. Barza M, Brown RB, Shanks C, Gamble C, Weinstein L. Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs. Antimicrob Agents Chemother 1975; 8:713–20.
37. Fabre J, Milek E, Kalfopoulos P, Mérier G. Tetracycline kinetics in man. Digestive absorption and serum concentration. Schweiz Med Wochenschr 1971; 101:593–8.
38. Gupta A, Khanna S. Repeat Clostridium difficile testing. JAMA 2016; 316:2422–3.
39. Scheurer DB, Hicks LS, Cook EF, Schnipper JL. Accuracy of ICD-9 coding for Clostridium difficile infections: a retrospective cohort. Epidemiol Infect 2007; 135:1010–3.